Pharmacyclics CEO takes aim at FDA decision-making

Dendreon isn't the only developer that has a beef with the FDA. Pharmalot writes up the case of Pharmacyclics CEO Richard Miller, who has found a soap box on some high profile news outlets to take the agency to task for rejecting the company's cancer drug. Miller's been on CNBC and on the op-ed pages of the Wall Street Journal to make the case that experimental drugs for terminal diseases should be treated differently than traditional meds.

"The FDA seems to be using a one-size-fits-all approach and seems to be regulating drugs that are intended for serious disease, life-threatening diseases, the same way they might regulate a drug that's used to treat a headache," says Miller.

- read the report from Pharmalot

Related Articles:
Industry exec says FDA approval process too strict. Report
FDA quick to reject drugs as it gets more cautious. Report